Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
NCT04215445Phase 4Unknown
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Dec 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Universiti Kebangsaan Malaysia. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04215445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215445.